Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 522 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Failure Clear all
Recruiting Not applicable Interventional

Use of ReDS Technology in Patients With Acute Heart Failure

NCT04305717
View directory record Official record
Conditions
Heart Failure, Lung Congestion
Interventions
ReDS-guided strategy
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 13, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
TX000045- Dose A, TX000045- Dose B, Placebo
Drug
Lead sponsor
Tectonic Therapeutic
Industry
Eligibility
18 Years to 83 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Comparison of Primary Extubation Failure Between NIPPV and NI-NAVA

NCT03242057
View directory record Official record
Conditions
Preterm Infant, BPD - Bronchopulmonary Dysplasia, Barotrauma
Interventions
NAVA, NIPPV
Other
Lead sponsor
University of Florida
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 13, 2026, 5:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

NCT04409509
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Bradenton, Florida • St. Petersburg, Florida • Mason City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 13, 2026, 5:34 AM EDT
Recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
46
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NCT02973789
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, NSCLC
Interventions
NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
Device · Drug
Lead sponsor
NovoCure GmbH
Industry
Eligibility
22 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
73
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

NCT04311697
View directory record Official record
Conditions
Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions
Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
Drug
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 100 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 13, 2026, 5:34 AM EDT
Active, not recruiting Not applicable Interventional

Transitional Care Model Evaluation 2020

NCT04212962
View directory record Official record
Conditions
CHF - Congestive Heart Failure, COPD, Pneumonia
Interventions
Transitional care model (TCM), Usual care
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
65 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 13, 2026, 5:34 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease (cGVHD)
Interventions
Vimseltinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Exercise Pulmonary Transit Time

NCT04336995
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
contrast echocardiography
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

NCT00294736
View directory record Official record
Conditions
NSCLC
Interventions
Tarceva
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bakersfield, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Method To Measure Protein Digestion & Absorption

NCT02065141
View directory record Official record
Conditions
Chronic Heart Failure, Pulmonary Disorder, Chronic Obstructive
Interventions
sip feeding with stable isotope infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 13, 2026, 5:34 AM EDT
Recruiting Phase 2 Interventional

Repurposing Valsartan May Protect Against Pulmonary Hypertension

NCT06053580
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder
Interventions
Valsartan 40 mg, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 13, 2026, 5:34 AM EDT
Active, not recruiting No phase listed Observational

Long Term Outcomes of Patients With COVID-19

NCT04360538
View directory record Official record
Conditions
Critical Illness, Corona Virus Infection, Respiratory Failure, Covid-19
Interventions
Quality of Life, Impact Event Score, Hospital anxiety and depression scale
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 13, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
Oral treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Lift Mobile Mindfulness for COVID-19 Distress Symptoms

NCT04581200
View directory record Official record
Conditions
COVID-19, Cardiorespiratory Failure
Interventions
Lift
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 13, 2026, 5:34 AM EDT
Not listed No phase listed Observational

Hospital-wide Incidence, Clinical Characteristics and Outcomes of ARDS

NCT03546699
View directory record Official record
Conditions
ARDS, Respiratory Failure, Lung Ultrasound
Interventions
Estimation of hospital-wide incidence of ARDS
Diagnostic Test
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 13, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

NCT03043651
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 13, 2026, 5:34 AM EDT
Withdrawn Not applicable Interventional

COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia

NCT04381923
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2, Hypoxemic Respiratory Failure, Pneumonia, Viral, COVID
Interventions
Helmet Continuous Positive Airway Pressure (CPAP), High Flow Nasal Oxygen (HFNO)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 13, 2026, 5:34 AM EDT
Not listed Not applicable Interventional

Does Ultrasound Assessment for Extravascular Lung Water and IVC Measurement Affect Outcomes in Inpatient Heart Failure Management?

NCT04436718
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Daily pocus exam
Diagnostic Test
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 13, 2026, 5:34 AM EDT
Not listed No phase listed Observational

Impact of Atelectasis on RVEDP Following Orthotropic Heart Transplantation

NCT06140810
View directory record Official record
Conditions
Heart Transplant Failure, Anesthesia
Interventions
Lung Recruitment
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 13, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Randomized Evaluation of Default Access to Palliative Services

NCT02505035
View directory record Official record
Conditions
COPD, ESRD, Dementia
Interventions
Default ordering of palliative consult
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
34,239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Bridgeport, Connecticut • Jacksonville, Florida • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 13, 2026, 5:34 AM EDT